555 related articles for article (PubMed ID: 30415909)
1. Combination Therapy With Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors in Older Patients With Type 2 Diabetes: A Real-World Evidence Study.
Carretero Gómez J; Arévalo Lorido JC; Gómez Huelgas R; García de Lucas D; Mateos Polo L; Varela Aguilar JM; Seguí Ripoll JM; Ena J;
Can J Diabetes; 2019 Apr; 43(3):186-192. PubMed ID: 30415909
[TBL] [Abstract][Full Text] [Related]
2. Effect of Hemoglobin A1c Reduction or Weight Reduction on Blood Pressure in Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Treatment in Type 2 Diabetes Mellitus: A Meta-Analysis.
Hu M; Cai X; Yang W; Zhang S; Nie L; Ji L
J Am Heart Assoc; 2020 Apr; 9(7):e015323. PubMed ID: 32223390
[TBL] [Abstract][Full Text] [Related]
3. Effect of combination pioglitazone with sodium-glucose cotransporter-2 inhibitors or glucagon-like peptide-1 receptor agonists on outcomes in type 2 diabetes: A systematic review, meta-analysis, and real-world study from an international federated database.
Anson M; Henney AE; Zhao SS; Ibarburu GH; Lip GYH; Cuthbertson DJ; Nabrdalik K; Alam U
Diabetes Obes Metab; 2024 Jul; 26(7):2606-2623. PubMed ID: 38558280
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists as complementary agents that address multi-organ defects in type 2 diabetes.
Lajara R
Postgrad Med; 2019 Nov; 131(8):555-565. PubMed ID: 31580737
[TBL] [Abstract][Full Text] [Related]
5. Clinical and Safety Outcomes With GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 1 Diabetes: A Real-World Study.
Edwards K; Li X; Lingvay I
J Clin Endocrinol Metab; 2023 Mar; 108(4):920-930. PubMed ID: 36268825
[TBL] [Abstract][Full Text] [Related]
6. Real-World Glycemic Control from GLP-1RA Therapy with and Without Concurrent Insulin in Patients with Type 2 Diabetes.
Singhal M; Unni S; Schauerhamer M; Nguyen H; Hurd J; McAdam-Marx C
J Manag Care Spec Pharm; 2017 Mar; 23(3):267-275. PubMed ID: 28230449
[TBL] [Abstract][Full Text] [Related]
7. Prescription Patterns of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Patients with Coronary Artery Disease.
Hofer F; Kazem N; Schweitzer R; Hammer A; Jakse F; Koller L; Hengstenberg C; Sulzgruber P; Niessner A
Cardiovasc Drugs Ther; 2021 Dec; 35(6):1161-1170. PubMed ID: 33666822
[TBL] [Abstract][Full Text] [Related]
8. All-cause mortality and cardiovascular outcomes with sodium-glucose Co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists and with combination therapy in people with type 2 diabetes.
Riley DR; Essa H; Austin P; Preston F; Kargbo I; Ibarburu GH; Ghuman R; Cuthbertson DJ; Lip GYH; Alam U
Diabetes Obes Metab; 2023 Oct; 25(10):2897-2909. PubMed ID: 37385958
[TBL] [Abstract][Full Text] [Related]
9. Glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors as add-on therapy for patients with type 2 diabetes? A systematic review and meta-analysis of surrogate metabolic endpoints.
Patoulias D; Katsimardou A; Kalogirou MS; Zografou I; Toumpourleka M; Imprialos K; Stavropoulos K; Stergiou I; Papadopoulos C; Doumas M
Diabetes Metab; 2020 Sep; 46(4):272-279. PubMed ID: 32437914
[TBL] [Abstract][Full Text] [Related]
10. Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12-Month Treatment.
Ikonomidis I; Pavlidis G; Thymis J; Birba D; Kalogeris A; Kousathana F; Kountouri A; Balampanis K; Parissis J; Andreadou I; Katogiannis K; Dimitriadis G; Bamias A; Iliodromitis E; Lambadiari V
J Am Heart Assoc; 2020 May; 9(9):e015716. PubMed ID: 32326806
[TBL] [Abstract][Full Text] [Related]
11. Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors as combination therapy for type 2 diabetes: A systematic review and meta-analysis.
Mantsiou C; Karagiannis T; Kakotrichi P; Malandris K; Avgerinos I; Liakos A; Tsapas A; Bekiari E
Diabetes Obes Metab; 2020 Oct; 22(10):1857-1868. PubMed ID: 32476254
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: A meta-analysis.
Castellana M; Cignarelli A; Brescia F; Perrini S; Natalicchio A; Laviola L; Giorgino F
Sci Rep; 2019 Dec; 9(1):19351. PubMed ID: 31852920
[TBL] [Abstract][Full Text] [Related]
13. Risks of stroke, its subtypes and atrial fibrillation associated with glucagon-like peptide 1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: a real-world population-based cohort study in Hong Kong.
Lui DTW; Tang EHM; Wu T; Au ICH; Lee CH; Woo YC; Tan KCB; Wong CKH
Cardiovasc Diabetol; 2023 Feb; 22(1):40. PubMed ID: 36829226
[TBL] [Abstract][Full Text] [Related]
14. The Effect of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors in Patients Prescribed Regular U-500 Insulin.
Meade LT; Mannka ML
Ann Pharmacother; 2019 Nov; 53(11):1111-1116. PubMed ID: 31215219
[No Abstract] [Full Text] [Related]
15. Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM).
Gourdy P; Darmon P; Dievart F; Halimi JM; Guerci B
Cardiovasc Diabetol; 2023 Apr; 22(1):79. PubMed ID: 37005640
[TBL] [Abstract][Full Text] [Related]
16. Long-term safety and efficacy of the sodium-glucose cotransporter 2 inhibitor, tofogliflozin, added on glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52-week open-label, multicenter, post-marketing clinical study.
Terauchi Y; Fujiwara H; Kurihara Y; Suganami H; Tamura M; Senda M; Gunji R; Kaku K
J Diabetes Investig; 2019 Nov; 10(6):1518-1526. PubMed ID: 31033218
[TBL] [Abstract][Full Text] [Related]
17. Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, and Dipeptidyl Peptidase-4 Inhibitors, and Risk of Hospitalization.
Lyu B; Grams ME; Chang A; Inker LA; Coresh J; Shin JI
Am J Cardiol; 2022 Feb; 165():124-130. PubMed ID: 34937658
[TBL] [Abstract][Full Text] [Related]
18. Glucagon-like peptide-1 receptor agonists and the risk of atrial fibrillation in adults with diabetes: a real-world study.
Xu Y; Boyle TA; Lyu B; Ballew SH; Selvin E; Chang AR; Inker LA; Grams ME; Shin JI
J Gen Intern Med; 2024 May; 39(7):1112-1121. PubMed ID: 38191976
[TBL] [Abstract][Full Text] [Related]
19. Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: A systematic review and meta-analysis of randomized controlled trials.
Patoulias D; Stavropoulos K; Imprialos K; Katsimardou A; Kalogirou MS; Koutsampasopoulos K; Zografou I; Papadopoulos C; Karagiannis A; Doumas M
Diabetes Res Clin Pract; 2019 Dec; 158():107927. PubMed ID: 31733280
[TBL] [Abstract][Full Text] [Related]
20. Cardio-renal outcomes and the direct medical cost of type 2 diabetes patients treated with sodium glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A population-based cohort study.
Tang EHM; Wong CKH; Lau KTK; Fei Y; Cheung BMY
Diabetes Res Clin Pract; 2021 Oct; 180():109071. PubMed ID: 34592391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
